EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT 14 April 2025 ─────────────────────────────────────── FDA Approval of WiSE ® CRT System Key highlights: EBR Systems has secured FDA approval for the WiSE CRT System—the world’s first and only leadless solution for left ventricular endocardial pacing. For the first time, clinicians can deliver cardiac resynchronization therapy without leads EBR will initially target a US$3.6 billion addressable market across high-risk upgrade, lead failure, and leadless CRT expansion categories, with future opportunity to expand into other indications. A focused, limited market release will begin in late 2025. Full-scale commercial launch follows in early 2026. Sunnyvale, California; 13 April 2025: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing device for heart failure, is pleased to announce the US Food and Drug Administration (FDA) approval of EBR's WiSE cardiac resynchronisation therapy (“CRT”) System. The FDA has issued an approval letter authorising the commercial marketing of EBR’s WiSE CRT System in the US. The FDA approva…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
EBR Systems, Inc.
EBRCZOTCEQUITYCurrent
Other Events
Item 8.01 Other Events. On April 13, 2025, EBR Systems, Inc. (the “Company”) issued a press release announcing that the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of its premarket approval application (PMA) for the WiSE CRT System and approved the WiSE CRT System for commercial distribution for adult patients who are at leas…
Company context
Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.